December 09, 2009 10:28 ET

Goldman Small Cap Research Initiates Coverage on MedClean Technologies (OTCBB: MCLN) With Speculative Buy Rating

LOS ANGELES, CA--(Marketwire - December 9, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that former Piper Jaffray's Technology analyst Rob Goldman, who brings over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager, has initiated coverage on MedClean Technologies Inc. (OTCBB: MCLN).

In his report (available as a download to members of BioMedReports) Goldman gives the stock a near-term target of $0.14 and an early 2010 price target of $0.40.

During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

The coverage report is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556